MétaCan
Menu
Retour à la cohorte
Enregistrement W2997572070 · doi:10.1176/appi.pn.2020.1a17

Women With Schizophrenia Only Half as Likely to Receive Mammograms

2020· article· en· W2997572070 sur OpenAlexaboutno aff
Mark Moran

Notice bibliographique

RevuePsychiatric News · 2020
Typearticle
Langueen
DomaineMedicine
ThématiqueGlobal Cancer Incidence and Screening
Établissements canadiensnon disponible
Organismes subventionnairesnon disponible
Mots-clésPopulationSchizophrenia (object-oriented programming)MedicinePsychiatryMental illnessEthnic groupMammographyPsychological interventionBreast cancerMental healthFamily medicineGerontologyCancerInternal medicineEnvironmental health

Résumé

récupéré en direct d'OpenAlex

Back to table of contents Previous article Next article Clinical & ResearchFull AccessWomen With Schizophrenia Only Half as Likely to Receive MammogramsMark MoranMark MoranPublished Online:3 Jan 2020https://doi.org/10.1176/appi.pn.2020.1a17AbstractThe findings of a meta-analysis suggest that physicians may need to do more to encourage women with schizophrenia to seek cancer screening.Women with schizophrenia are only half as likely as women in the general population to receive mammograms, reports a meta-analysis posted November 14, 2019, in Psychiatric Services in Advance.The finding helps explain previous research indicating that breast cancer is detected at later stages in women with serious mental illness and is characterized by larger and higher-grade tumors and more lymph node involvement.Lead author Alison Hwong, M.D., Ph.D., and colleagues at the University of California, San Francisco, wrote that further work is needed to understand underlying causes of the disparity in screening and to develop interventions to promote breast cancer screening for this vulnerable population."Our finding that women with schizophrenia and psychosis were about half as likely to be screened as the general population supports the argument that persons with severe mental illness should be designated as a health disparity population, with special funding to target disparities in care," they wrote. "Future studies are needed to determine whether women who have schizophrenia experience further differences in mammography screening rates on the basis of race or ethnicity."Hwong and colleagues compiled data from 11 clinical studies that looked at mammography screening rates of women with schizophrenia or other psychotic disorders. The 11 studies were conducted in four countries with diverse health care systems—seven in the United States, two in the United Kingdom, one in Denmark, and one in Canada—and in a range of settings (inpatient and outpatient settings, community clinics, and multisite research centers) with privately and publicly insured populations.The studies included data from 446,475 participants in control groups and 25,447 women with diagnoses of schizophrenia or other psychotic disorders. The primary outcome of interest was the rate of mammography screening for women with schizophrenia and psychotic disorders compared with that of the general eligible population.The pooled odds ratio from the 11 studies was 0.50 for women with schizophrenia (indicating they were half as likely as the general population to receive a mammography). The odds ratios in the seven studies from the United States varied dramatically from a high of 1.05 (indicating women with schizophrenia were actually more likely than the general population to get mammography screens) to a low of 0.04. The authors noted that one reason for the wide differences seen in the U.S. studies may be due to variations in severity of illness among women included the studies.Hwong and colleagues, as well as one expert who reviewed the report, suggested that logistics of scheduling appointments may be paramount in explaining the discrepancy in screening rates. "With time constraints, primary care providers and psychiatrists may not prioritize cancer screening for patients with serious mental illness," the authors wrote. Physicians may focus on psychiatric and metabolic symptoms first, which "may lead to deferring routine preventive screening discussion for future visits, but the future discussion never occursDeanna Kelly, Pharm.D., urges use of prolactin-sparing antipsychotics in women with schizophrenia who have family and other risk factors for breast cancer.Deanna Kelly, Pharm.D., director of the Treatment Research Program (TRP) at the Maryland Psychiatric Research Center, reviewed the report for Psychiatric News and said the findings are not surprising. She was the principal investigator of the DAAMSEL (Dopamine Partial Agonist, Aripiprazole, for the Management of Symptomatic Elevated Prolactin) trial looking at prolactin levels and galactorrhea in women receiving antipsychotic medication (Psychiatric News). As part of that trial, women were prospectively provided with breast exams, and Kelly said many women reported typically missing mammography appointments."I made several referrals for mammograms due to potential lumps and keloids," she said.She said typically women are commonly given an order for a mammogram during an annual appointment with an obstetrician-gynecologist, requiring a separate appointment for the exam. "I think one of the most challenging barriers is the logistics of scheduling appointments," she told Psychiatric News.She added that care coordination is less than ideal between mental health professionals and other medical professionals. "Given that breast cancer is higher in women with schizophrenia, and since we now know screening is subpar, those treating women with schizophrenia should inquire about general medical care that patients may or may not be receiving and encourage our patients to seek preventative care and see their physicians for regular checkups."Kelly added that there is some research—not conclusive—suggesting that some antipsychotics may increase risk for breast cancer. "We do know that some, although not all, antipsychotic medications increase prolactin, and we also know that the National Nurses' Health Study showed that higher prolactin was associated with higher rates of breast cancer in pre- and post-menopausal women."Kelly said clinicians should consider using prolactin-sparing antipsychotic medications in patients who have family and other risk factors for breast cancer, especially knowing that screening rates are not ideal. ■"Breast Cancer Screening in Women With Schizophrenia: A Systematic Review and Meta-Analysis" is posted here. "Bioactive Prolactin Levels and Risk of Breast Cancer: A Nested Case–Control Study" is posted here. ISSUES NewArchived

Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.

Comment cette classification a été obtenuedéplier

Prédiction distillée sur la base complète

Imitation des enseignants

Ni prévalence calibrée, ni vérité terrain. Validation humaine à venir. Apprise à partir de 10 348 étiquettes directes de Codex et de 10 348 étiquettes directes de Gemma. Le mode candidate est l'union des têtes enseignantes seuillées; le consensus est leur intersection. Ces sorties portent le statut machine_predicted_unvalidated et ne sont ni des étiquettes humaines ni des étiquettes directes de modèles de pointe.

score de la tête « metaresearch » (Codex)0,000
score de la tête « metaresearch » (Gemma)0,000
Version: codex-gemma-dda1882f352aStatut de validation: machine_predicted_unvalidated
Catégories candidatesCharge utile insuffisante (le modèle a refusé de juger)
Catégories consensuellesaucune
DomaineSignal candidat: aucune · Signal consensuel: aucune
Devis d'étudeSignal candidat: Sans objet · Signal consensuel: aucune
GenreSignal candidat: Empirique · Signal consensuel: Empirique
Score de désaccord entre enseignants0,636
Score d'incertitude au seuil1,000

Scores Codex et Gemma par catégorie

CatégorieCodexGemma
Métarecherche0,0000,000
Méta-épidémiologie (sens strict)0,0000,000
Méta-épidémiologie (sens large)0,0000,000
Bibliométrie0,0000,001
Études des sciences et des technologies0,0000,000
Communication savante0,0000,000
Science ouverte0,0000,000
Intégrité de la recherche0,0000,000
Charge utile insuffisante (le modèle a refusé de juger)0,0000,001

Scores machine (provisoires)

Les deux têtes enseignantes du modèle étudiant, lues sur ce travail. Un score ordonne la base pour la relecture; il n'affirme jamais une catégorie, et le statut de validation accompagne chaque rangée tel quel.

Scores de référence d'un modèle non mature (critères de maturité non atteints, 7 itérations). Un score ordonne; il n'affirme jamais une catégorie.

Tête enseignante Opus0,040
Tête enseignante GPT0,298
Écart entre enseignants0,258 · la distance entre les deux têtes enseignantes sur ce seul travail
Statut de validationscore_only:v0-immature-baseline · tel quel depuis la passe de notation : score_only signifie que le nombre peut ordonner les travaux, et qu'aucune étiquette de catégorie n'en découle

Classification

machine, non validée

Prédiction automatique; un appel candidat d’une seule tête enseignante, pas un consensus.

Devis d'étudeSans objet
Domainenon disponible
GenreEmpirique

Le détail, modèle par modèle et score par score, se trouve en fin de page sous « Comment cette classification a été obtenue ».

En bref

Citations0
Publié2020
Routes d'admission1
Résumé présentoui

Explorer davantage

Même revuePsychiatric NewsMême sujetGlobal Cancer Incidence and ScreeningTravaux en français237 207